Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the…
The first Enterprise Quality Management Solution in the industry with expanded capabilities for European Union Medical Device Regulation regulations and…
NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Kourous A. Rezaei, MD, Chief Medical Officer of IVERIC bio,…
Industry veteran to drive partnerships to discover and develop first-in-class treatments for a wide range of diseases MOUNTAIN VIEW, Calif.–(BUSINESS…
New Certara DApp provides transaction insights on Hedera network and supports data provenance for supply chain uses cases, improving transparency…
– First Presentation of Initial Data from a Phase 1 Trial of Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced or…
LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #Aim2TreatAlopeciaAreata—Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label…
The Janssen has filed for a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking first-in-class approval of guselkumab brand Tremfya, for the treatment of adult patients with active psoriatic arthritis (PsA), and expects to submit a marketing application to the European Medicines Agency seeking approval of TREMFYA as a treatment for PsA before the end of the year.
The addition of daratumumab – or in this particular study – Darzalex to bortezomib, lenalidomide and dexamethasone (VRd) induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation (ASCT) compared with VRd alone.
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment with ACE-083 in patients with facioscapulohumeral muscular dystrophy (FSHD) did not achieve functional secondary endpoints in the Phase 2 tria